dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Massó Vallés, Daniel |
dc.contributor.author | Soucek, Laura |
dc.date.accessioned | 2021-09-01T10:59:26Z |
dc.date.available | 2021-09-01T10:59:26Z |
dc.date.issued | 2020-04-04 |
dc.identifier.citation | Massó-Vallés D, Soucek L. Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. Cells. 2020 Apr 4;9(4):883. |
dc.identifier.issn | 2073-4409 |
dc.identifier.uri | https://hdl.handle.net/11351/6251 |
dc.description | Myc inhibition; Cancer; Omomyc |
dc.description.abstract | First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice, and has shown remarkable anti-cancer properties in a wide range of tumor types. The recently described therapeutic effect of purified Omomyc mini-protein—following the surprising discovery of its cell-penetrating capacity—constitutes a paradigm shift. Now, much more than a proof of concept, the most characterized Myc inhibitor to date is advancing in its drug development pipeline, pushing Myc inhibition into the clinic. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cells;9(4) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Fosfoproteïnes - Inhibidors |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | Proto-Oncogene Proteins c-myc |
dc.subject.mesh | /therapeutic use |
dc.title | Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cells9040883 |
dc.subject.decs | neoplasias |
dc.subject.decs | proteínas protooncogénicas c-myc |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://www.mdpi.com/2073-4409/9/4/883 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Massó-Vallés D] Peptomyc, Barcelona, Spain. [Soucek L] Peptomyc, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 32260326 |
dc.identifier.wos | 000535559500094 |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020/872212 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI16/2F01224 |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020/617473 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |